Hepquant.com Website Review

HepQuant: A minimally invasive as*essment of chronic liver disease. LIVER FUNCTION TESTS: BREAKING THROUGH CONVENTIONAL THINKING ABOUT LIVER HEALTH TESTING. HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for as*essing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive. Drug Targets” in Boston, Sep. 25-28 (#BostonDOT18). The conference brings together current and emerging “hot” targets, technologies and validation strategies for the development of novel small molecules and biologics.  in San Francisco in November. The event will be held Nov. 9 – 13th and is typically attended by more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world.   (More info. HepQuant presented a poster at Nash Summit 2018: “Identifying Potential Subjects for NASH Clinical Trials Using the HepQuant Debrief.  For AASLD member access to the presentation, please click here Here is a link to our 2017 AASLD presentation on “Diagnosing NASH and As*essing NASH Disease Severity with HepQuant-STAT, a Simple Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process.